Study of Inhaled Tranexamic Acid to Treat Lung Bleeding in Cancer Patients on Mechanical Ventilation

What this Trial Is About

Researchers are evaluating whether inhaled tranexamic acid can improve survival in patients who have cancer-related pulmonary hemorrhage and respiratory failure. This study compares the effects of nebulized tranexamic acid to usual care in patients with hematologic malignancies who are on mechanical ventilation. The trial aims to assess mortality rates and other clinical outcomes in this serious condition. Participants are assigned to receive either 500 mg of nebulized tranexamic acid every 8 hours for at least 3 days and up to 5 days or continue with usual care. This study follows a non-randomized, controlled design with the primary focus on treatment effects. The intervention is delivered via inhalation through a nebulizer, and the study is conducted under medical supervision. During the study, participants are monitored for mortality up to 28 days and other outcomes such as time to control pulmonary bleeding, ventilator days, length of stay in ICU and hospital, oxygenation ratio changes, recurrence of bleeding, and need for invasive procedures. Assessments include clinical evaluations and respiratory support monitoring. The total study duration spans from enrollment through 30 days of outcome assessment, with safety and effectiveness measures collected throughout.

A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients